IP Library Patent Application 19264249
Patent Application
App. No. 19/264,249

BIDIRECTIONAL MULTI-ENZYMATIC SCAFFOLDS FOR BIOSYNTHESIZING CANNABINOIDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/264,249
Abstract

This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.

Claims (23)

1 . A host cell comprising:

(a) a first exogenous nucleic acid encoding a first polypeptide having ATP citrate lyase activity and comprising a first heterologous interaction domain,

(b) a second exogenous nucleic acid encoding a second polypeptide having acetyl-CoA acetyltransferase activity and comprising a second heterologous interaction domain, and

(c) a third exogenous nucleic acid encoding a polypeptide scaffold comprising a peptide ligand for each of said first and second heterologous interaction domains,

wherein each of said first and second heterologous interaction domains is different,

wherein each peptide ligand for each of said first and second heterologous interaction domains is different,

wherein said polypeptide scaffold comprises, in an order extending from amino terminus to carboxy terminus, a first copy of said peptide ligand for said first heterologous interaction domain, a first copy of said peptide ligand for said second heterologous interaction domain, a second copy of said peptide ligand for said second heterologous interaction domain, and a second copy of said peptide ligand for said first heterologous interaction domain.

2 . The host cell of claim 1 , wherein said host cell is a bacterial or a yeast host cell.

3 . The host cell of claim 2 , wherein said bacterial cell is selected from the group consisting of Escherichia coli, Bacillus, Brevibacterium, Streptomyces , and Pseudomonas cells.

4 . The host cell of claim 2 , wherein said yeast cell is selected from the group consisting of Pichia pastoris, Saccharomyces cerevisiae, Yarrowia lipolytica, Kluyveromyces marxianus , and Komagataella phaffii cells.

5 . The host cell of claim 1 , wherein said host cell is an algae or a plant cell.

6 . The host cell of claim 5 , wherein said algae is Dunaliella sp., Chlorella variabilis, Euglena mutabilis , or Chlamydomonas reinhardtii cells.

7 . The host cell of claim 5 , wherein said plant cell is a Cannabis or tobacco cell.

8 . The host cell of claim 1 , wherein each of said first and second polypeptides is of the formula: enzyme—linker 1 —spacer—linker 2 —motif 1 —linker 3 —motif 2 , wherein linker 1 , linker 2 , and linker 3 are the same or different, wherein motif 1 and motif 2 are the same or different, and wherein motif 1 and motif 2 form said heterologous interaction domain.

9 . The host cell of claim 8 , wherein said scaffold polypeptide comprises a linker between each adjacent peptide ligand.

10 . The host cell of claim 9 , wherein said scaffold polypeptide is tagged with a MYC tag, FLAG tag, or HA tag.

11 . The host cell of claim 9 , wherein said linker is a flexible GS-rich sequence flanking a rigid α-helical moiety.

12 . The host cell of claim 9 , wherein said spacer is the cTPR6 spacer.

13 . The host cell of claim 1 , wherein a constitutive promoter is operably linked to one or both of said exogenous nucleic acids encoding said polypeptides or to said third exogenous nucleic acid encoding said polypeptide scaffold.

14 . The host cell of claim 1 , wherein a first constitutive promoter is operably linked to one or both of said exogenous nucleic acids encoding said polypeptides and a second constitutive promoter is operably linked to said third exogenous nucleic acid encoding said polypeptide scaffold.

15 . The host cell of claim 14 , wherein said constitutive promoter used to express said polypeptide scaffold has weaker constitutive activity level than said constitutive promoter used to express said polypeptides.

16 . The host cell of claim 1 , wherein each said exogenous nucleic acid comprises an inducible promoter operably linked to the sequence encoding said polypeptide or said polypeptide scaffold.

17 . The host cell of claim 16 , wherein said promoter is the GAL1-10 promoter.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2025
From: BUCK, JORDAN
To: KHONA PHARMS LLC
Reel/Frame 071807/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2025
From: KHONA PHARMS LLC
To: KHONA SCIENTIFIC, LLC
Reel/Frame 071807/0348 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2025
From: KHONA SCIENTIFIC, INC.
To: KHONA SCIENTIFIC HOLDINGS, INC.
Reel/Frame 071807/0594 →
SECURITY INTEREST Recorded Jul 23, 2025
From: KHONA SCIENTIFIC HOLDINGS, INC.
To: ORLADY, PAUL; SHORTAL, JOSEPH
Reel/Frame 071808/0228 →
CONVERSION Recorded Jul 23, 2025
From: KHONA SCIENTIFIC, LLC
To: KHONA SCIENTIFIC, INC.
Reel/Frame 073417/0544 →